biostudies-literatureUnknown36(3)Gangwani MK<h4>Background</h4>Crohn's disease is a relapsing disease that often requires operative management. Prevention of postoperative recurrence (POR) is critical to maintain remissions. Biologic agents have proven to be most successful in remission maintenance. We made a direct head-to-head comparison of the 2 anti-tumor necrosis factor agents, infliximab (IFX) and adalimumab (ADA), to compare endoscopic and clinical POR of Crohn's disease.<h4>Methods</h4>We conducted a comprehensive literature search in 7 databases, including Medline, Embase, Cochrane Central Register of Controlled Trials, Web of Science Core Collection, KCI-Korean Journal Index, SciELO, and Global Index Medicus. Odds ratios (OR) were calculated with 95% confidence intervals (CI) and P-values (<0.05 considered significant). WeAnnals of gastroenterology293-299https://www.ebi.ac.uk/biostudies/studies/S-EPMC10152807biostudies-literatureComparing adalimumab and infliximab in the prevention of postoperative recurrence of Crohn's disease: a systematic review and meta-analysis.PMC10152807Dahiya DSAhmed ZAziz MKobeissy AGangwani MKLee-Smith WKamal FNawras MKarna RAlastal YSohail AHPriyanka FRani AfalseComparing adalimumab and infliximab in the prevention of postoperative recurrence of Crohn's disease: a systematic review and meta-analysis.<h4>Background</h4>Crohn's disease is a relapsing disease that often requires operative management. Prevention of postoperative recurrence (POR) is critical to maintain remissions. Biologic agents have proven to be most successful in remission maintenance. We made a direct head-to-head comparison of the 2 anti-tumor necrosis factor agents, infliximab (IFX) and adalimumab (ADA), to compare endoscopic and clinical POR of Crohn's disease.<h4>Methods</h4>We conducted a comprehensive literature search in 7 databases, including Medline, Embase, Cochrane Central Register of Controlled Trials, Web of Science Core Collection, KCI-Korean Journal Index, SciELO, and Global Index Medicus. Odds ratios (OR) were calculated with 95% confidence intervals (CI) and P-values (<0.05 considered significant). We2023-01-01T00:00:00Z2023 May-Jun2025-04-27T03:15:49.789Z2025-02-19T02:25:51.481ZS-EPMC101528073714401910.20524/aog.2023.0786